- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind stock is suffering, and the company appears to be in trouble.
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.